Drug Trial Radar · NCT06049290
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
342
Planned (sponsor's estimate)
Start
Oct 20, 2023
Primary completion
Sep 20, 2029
Study completion Sep 20, 2029
Sponsor
- Lead sponsor
- Nanjing Leads Biolabs Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evaluate the safety, tolerability, PK profile, immunogenicity and efficacy of LBL-034.
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
LBL-034 for InjectionDrug
Q2W; intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy).
- Dose-limiting toxicities(DLT)Time frame: The DLT observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).
- Maximum tolerated dose (MTD)Time frame: The MTD observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).
- Occurrence of adverse event (AE) and serious adverse event (SAE)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China · Recruiting
The Afliliated Hospital of Guizhou Medical Univeristy
Guiyang, Guizhou, China · Recruiting
The Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China · Recruiting
The First Affiliated Hospital of Henan University
Luoyang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First Bethune Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Shengjing Hospital of China Medical University
Shengyang, Liaoning, China · Recruiting
Qingdao Municipal Hospital
Qingdao, Shandong, China · Recruiting
Shanghai Fourth People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
Xi’an, Shanxi, China · Recruiting
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.